EMBR-16. SMOOTHENED-ACTIVATING LIPIDS DRIVE RESISTANCE TO CDK4/6 INHIBITION IN HEDGEHOG-ASSOCIATED MEDULLOBLASTOMA

por Daggubati, Vikas, Hochstelter, Jordan, Bommireddy, Anirudh, Choudhury, Abrar, Krup, Alexis Leigh, Choski, Pervinder, Tong, Pakteema, Li, Amy, Xu, Libin, Reiter, Jeremy, Raleigh, David
Publicado 2021

Clinical Outcomes of Patients With Unresectable Primary Liver Cancer Treated With Yttrium-90 Radioembolization With an Escalated Dose

por Chin, Re-I, Bommireddy, Anirudh, Fraum, Tyler J., Ludwig, Daniel R., Huang, Yi, Zoberi, Jacqueline E., Garcia-Ramirez, Jose L., Maughan, Nichole M., Chapman, William, Korenblat, Kevin, Henke, Lauren E., Kim, Hyun, Badiyan, Shahed N.
Publicado 2022

Clinical outcomes of patients with unresectable primary liver cancer treated with MR-guided stereotactic body radiation Therapy: A Six-Year experience

por Chin, Re-I, Schiff, Joshua P., Bommireddy, Anirudh, Kang, Kylie H., Andruska, Neal, Price, Alexander T., Green, Olga L., Huang, Yi, Korenblat, Kevin, Parikh, Parag J, Olsen, Jefferey, Samson, Pamela P., Henke, Lauren E., Kim, Hyun, Badiyan, Shahed N.
Publicado 2023